EP05: “World Cancer Day”- Advancing Precision Cancer Care with OncoDNA & MGI
World Cancer Day, observed annually on February 4th, is a global initiative led by the Union for International Cancer Control (UICC) to raise awareness about cancer and encourage prevention, detection, and treatment efforts worldwide.
As we commemorate World Cancer Day 2025, MGI highlights the transformative role of genomics in precision oncology. This year’s theme, “United by Unique,” underscores the power of collaboration and innovation in the fight against cancer.
In this latest episode of the MGI Podcast, MGI welcomes leading industry experts to share their insights on the rapidly evolving landscape of genomic medicine. Together, they explore how cutting-edge advancements and multi-entity collaborations are revolutionizing cancer research, diagnosis, and treatment—bringing them closer to a future where personalized care leads to better outcomes.
Tune in below to join the conversation!
MGI Podcast EP05: “World Cancer Day”- Advancing Precision Cancer Care with OncoDNA & MGI
Watch EP04 "Using Gene Sequencing Technology to Enhance Anti-doping Efforts in Sports" Now
Dr. Cheng Boon is the Medical Director UK for OncoDNA, a leading NGS/genomics company specializing in precision oncology. With over 12 years of experience, Cheng is highly skilled in treating head and neck, upper GI, and hepatobiliary cancers using radiotherapy, chemotherapy, and advanced biological therapies, including immunotherapy (Nivolumab, Atezolizumab, Pembrolizumab, Durvalumab).
A strong advocate for personalized medicine, Cheng believes in utilizing genetic profiling to enhance treatment outcomes while minimizing toxicities. His research includes participation in national and international trials, particularly in pre-operative chemo-radiotherapy for oesophageal cancer to improve surgical success rates.
Dr Gareth Gerrad is a clinical Scientist with expertise in research, education, and innovation, specializing in haematological malignancies and, more recently, adult solid tumours.
He has experience integrating molecular and genomic techniques across clinical, academic, and private sectors to advance precision medicine and improve patient outcomes.
Filips Oļeškovs holds a master’s degree in biotechnology from Wageningen University & Research in the Netherlands, following a bachelor’s degree in chemistry from Riga Technical University.
Upon returning to Latvia, Filips joined MGI Latvia to gain hands-on experience in science-intensive projects. As a Field Application Developer in the biotech industry, he specializes in adapting and optimizing DNA sequencing processes to meet diverse customer requirements across Europe. His work also involves developing new DNA extraction and sequencing methods to advance precision genomics.
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Their focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. They provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries.
Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit https://en.mgi-tech.com/ , Linkedin, X, and Youtube.
